Enzon Inc, Rhone-Poulenc Rorer Inc deal

RPR received a non-exclusive license to use ENZN's Single-Chain Antigen-Binding (SCA) protein technology for intracellular expression of SCA proteins and for targeted vectors in the field of cell and gene therapy. RPR's Gencell division will apply the technology to its in vivo and ex vivo gene therapy programs in cancer, cardiovascular disease and immunology.

ENZN will receive a $1 million license fee and undisclosed milestone payments, plus a royalty on sales of products incoporating the technology. ...